Lifesciences Iii, L.P.Claru… Net Worth

The estimated Net Worth of Lifesciences Iii, L.P.Claru… is at least $28.8 Million dollars as of 2 July 2018. Lifesciences Claru owns over 200,000 units of Forty Seven stock worth over $28,817,980 and over the last few years Lifesciences sold FTSV stock worth over $0.

Lifesciences Claru FTSV stock SEC Form 4 insider trading

Lifesciences has made over 1 trades of the Forty Seven stock since 2018, according to the Form 4 filled with the SEC. Most recently Lifesciences bought 200,000 units of FTSV stock worth $3,200,000 on 2 July 2018.

The largest trade Lifesciences’s ever made was buying 200,000 units of Forty Seven stock on 2 July 2018 worth over $3,200,000. On average, Lifesciences trades about 200,000 units every 0 days since 2018. As of 2 July 2018 Lifesciences still owns at least 3,816,951 units of Forty Seven stock.

You can see the complete history of Lifesciences Claru stock trades at the bottom of the page.

Insider trading at Forty Seven

Over the last few years, insiders at Forty Seven have traded over $4,118,522 worth of Forty Seven stock and bought 2,621,245 units worth $41,666,515 . The most active insider traders include Tench Coxe, Michael L Speiser, and Jeffrey W Bird. On average, Forty Seven executives and independent directors trade stock every 7 days with the average trade being worth of $569,591. The most recent stock trade was executed by Mark Anthony Mc Camish on 20 May 2019, trading 16,500 units of FTSV stock currently worth $80,520.

What does Forty Seven do?

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

What does Forty Seven’s logo look like?

Complete history of Lifesciences Claru stock trades at Forty Seven

Forty Seven executives and stock owners

Forty Seven executives and other stock owners filed with the SEC include:

  • Mark McCamish, President, Chief Executive Officer, Director
  • Ann Rhoads, Chief Financial Officer
  • Chris Takimoto, Chief Medical Officer
  • Ian Clark, Independent Director
  • Craig Gibbs, Chief Business Officer
  • Kristine Ball, Independent Director
  • Jeffrey Bird, Lead Independent Director
  • Dennis Henner, Independent Director
  • Ravindra Majeti, Independent Director
  • Irving Weissman, Independent Director
  • Samuel J Iii Pullara,
  • Harbor Master Investors (Ca…, 10% owner
  • Michael L Speiser, 10% owner
  • Stefan A Dyckerhoff,
  • Venture Partners X, L.P.Lig…,
  • Hill Ventures Sutter,
  • Peter Nieh, 10% owner
  • Christopher J Schaepe, Director
  • Tench Coxe, 10% owner
  • Dennis Henner, Director
  • James N White, 10% owner
  • Venture Partners Select Ii,…,
  • Ravi Mhatre, 10% owner